Multiple Endocrine Neoplasia

The answer first

Multiple Endocrine Neoplasia is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Multiple Endocrine Neoplasia to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Thelen AE, Hogan EM, Su MW, McHenry CR The Genetics of Familial Neoplastic Thyroid Disease and Primary Hyperparathyroidism Surg Clin North Am, 2026.PMID 42419309
2. [2]Noso S, Miki H, Hiromine Y, Babaya N, et al. Metachronous multiple insulinomas in oculo-facio-cardio-dental syndrome harboring a novel BCOR deletion: a case report with review of literature Endocr J, 2026.PMID 42324136
3. [3]Nosé V, Canberk S, Baloch Z Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management Adv Anat Pathol, 2026.PMID 42319956
4. [4]Pawlak KM, Jagielski M, Papanikolaou IS, Hong W, et al. Pancreatic cystic lesions in hereditary syndromes: Diagnostic role of endoscopic ultrasound Best Pract Res Clin Gastroenterol, 2026.PMID 42167859
5. [5]Mariën L, Chhajlani S, De Herdt C, Ceulemans K, et al. Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence J Neuroendocrinol, 2026.PMID 42140697
6. [6]Moura MJ, Chatterjee A, Wali S, Garza DR, et al. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review Expert Opin Drug Saf, 2026.PMID 41995025
7. [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
8. [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
9. [9]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
10. [10]Mohammadifard MJ, Taghinejad A, AghaeiMeybodi F Coexistence of Multiple Endocrine Neoplasia Type 2B and Centri-Acinar Emphysema With Alpha-1 Antitrypsin Deficiency: A Case Report Respirol Case Rep, 2026.PMID 42459594
11. [11]Balderrama-Brondani V, Marcal L, Moussa MJ, Long JP, et al. Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study Endocr Pathol, 2026.PMID 42467395
12. [12]Santucci N, Caillot J, Binquet C, Goudet P, et al. Distal pancreatectomy for neuroendocrine neoplasms in patients with multiple endocrine neoplasia type 1 J Visc Surg, 2026.PMID 42442980